John Curnutte
Director/Board Member bei PLIANT THERAPEUTICS, INC.
Vermögen: 436 242 $ am 31.03.2024
Profil
John T.
Curnutte was the founder of Sagimet Biosciences, Inc. (founded in 2007) where he served as the Chief Executive Officer from 2007 to 2010.
He is currently working as an Independent Director at Pliant Therapeutics, Inc. since 2017.
In his former positions, Dr. Curnutte worked as the Chief Executive Officer at Sagimet Biosciences, Inc. from 2008 to 2010.
He also held the position of Senior Director at Genentech, Inc. in 2000.
Additionally, he served as an Independent Director at Diadexus, Inc. from 2015 to 2016, and as an Independent Non-Executive Director at Orchard Therapeutics Plc from 2019 to 2024.
From 2011 to 2019, he was the Co-President and EVP-Research & Development at Portola Pharmaceuticals LLC.
He was the President of Schering-Plough Biopharma in 2008.
Furthermore, he was a Member-Medical Staff at Stanford University School of Medicine from 1993 to 2013.
He also held positions as a Senior Advisor at Samsara Biocapital LLC and as a Senior Vice President-Discovery Research at Schering-Plough Research Institute.
Dr. Curnutte obtained his doctorate degree from Harvard Medical School in 1973 and his undergraduate degree from Harvard University in 1980.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 07.06.2023 | 29 278 ( 0,05% ) | 436 242 $ | 31.03.2024 |
Aktive Positionen von John Curnutte
| Unternehmen | Position | Beginn |
|---|---|---|
| PLIANT THERAPEUTICS, INC. | Director/Board Member | 01.08.2017 |
Ehemalige bekannte Positionen von John Curnutte
| Unternehmen | Position | Ende |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Director/Board Member | 24.01.2024 |
| PORTOLA PHARMACEUTICALS, INC. | President | 01.08.2018 |
| DIADEXUS, INC. | Director/Board Member | 01.06.2016 |
| Stanford University School of Medicine | Corporate Officer/Principal | 01.01.2013 |
| SAGIMET BIOSCIENCES INC. | Chief Executive Officer | 01.03.2010 |
Ausbildung von John Curnutte
| Harvard University | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SAGIMET BIOSCIENCES INC. | Health Technology |
| PLIANT THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Schering-Plough Research Institute
 Schering-Plough Research Institute Medical SpecialtiesHealth Technology Schering-Plough Research Institute provides pharmaceutical research. The company is headquartered in Kenilworth, NJ. | Health Technology |
Schering-Plough Biopharma
 Schering-Plough Biopharma Miscellaneous Commercial ServicesCommercial Services Part of Merck & Co., Inc., Schering-Plough Biopharma is a private company that provides pharmaceutical research services. The company is based in Kenilworth, NJ. | Commercial Services |
Diadexus, Inc.
 Diadexus, Inc. BiotechnologyHealth Technology Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
Samsara Biocapital LLC
 Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Finance |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
